Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma, not otherwise specified

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2893-2899

  Niitsu, Nozomi ^a,b   Nakamine, Hirokazu ^b   Okamoto, Masataka ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Adult Lymphoma Treatment Study Group ALTSG   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; NUCLEOSIDE DIPHOSPHATE KINASE A; ONCOPROTEIN; PROTEIN TIA 1; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW DISEASE; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA NOT OTHERWISE SPECIFIED; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; CYTOPLASM; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MIDDLE AGED; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955507940     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2999     Document Type: Article

References (20)

1. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
2. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 2008;26:152-8.
3. Shipp MA. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
4. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-9.
5. Niitsu N, Okabe-Kado J, Kasukabe T, Akamatsu H, Higashihara M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999;94:3541-50. (Pubitemid 29536150)
6. Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S, et al. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001;97:1202-10. (Pubitemid 32183740)
7. Niitsu N, Nakamine H, Okamoto M, Akamatsu H, Higashihara M, Honma Y, et al. Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma. Clin Cancer Res 2004;10:2482-90. (Pubitemid 38445710)
8. Niitsu N, Okamoto M, Aoki S, Miura I, Hirano M. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Haematol 2006;85:374-80.
9. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Volume 2. IARC WHO Classification of Tumours, No 2. Lyon, France: IARC Press; 2008.
10. Niitsu N, Nakamine H, Okamoto M, Tamaru JI, Hirano M, et al. A clinicopathological study of nm23-H1 expression in classical Hodgkin lymphoma. Ann Oncol 2008;19:1941-6.
11. Shresta S,PhamCT,ThomasDA, GraubertTA, Ley TJ.Howdocytotoxic lymphocytes kill their targets?Curr Opin Immunol 1998;10:581-7.
12. Felger RE, Macon WR, Kinney MC, Roberts S, Pasha T, Salhany KE. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 1997;150:1893-900. (Pubitemid 27233062)
13. Asano N, Suzuki R, Kagami Y, Ishida F, Kitamura K, Fukutani H, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 2005;10:1284-93. (Pubitemid 41368762)
14. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
15. MacDonald NJ, De La Rosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 1995;31A:1096-100.
16. Ferenc T, Lewinski A, Lange D, Niewiadomska H, Sygut J, Sporny S, et al. Analysis of NM23-H1 protein immunoreactivity in follicular thyroid tumors. Pol J Pathol 2004;55:149-53. (Pubitemid 40321623)
17. Steeg PS, Horak CE, Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 2008;14:5006-12.
18. Savage K, Ferreri AJ, Zinzani PL, Pileri SA. Peripheral T-cell lymphoma- not otherwise specified. Crit Rev Oncol Hematol 2010 Aug 9. [Epub ahead of print].
19. Otsuki Y, Tanaka M, Yoshii S, Kawazoe N, Nakaya K, Sugimura H. Tumor metastasis suppressor nm23H1 regulates Rac GTPase by interaction with Tiam1. Proc Natl Acad Sci U S A 2001;98:4385-90. (Pubitemid 32294986)
20. Okabe-Kado J, Kasukabe T. Physiological and pathological relevance of extracellular NM23/NDP kinases. J Bioenerg Biomembr 2003;35:89-93. (Pubitemid 36667585)